MX354822B - Metodos para la deteccion de anticuerpos neutralizantes anticitomegalovirus. - Google Patents
Metodos para la deteccion de anticuerpos neutralizantes anticitomegalovirus.Info
- Publication number
- MX354822B MX354822B MX2014011504A MX2014011504A MX354822B MX 354822 B MX354822 B MX 354822B MX 2014011504 A MX2014011504 A MX 2014011504A MX 2014011504 A MX2014011504 A MX 2014011504A MX 354822 B MX354822 B MX 354822B
- Authority
- MX
- Mexico
- Prior art keywords
- hcmv
- detection
- neutralizing antibodies
- methods
- virus
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 230000001512 anti-cytomegaloviral effect Effects 0.000 title 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000001917 fluorescence detection Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/04—Varicella-zoster virus
- G01N2333/045—Cytomegalovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a métodos útiles para determinar los niveles de infección por HCMV en las células hospederas, y por extensión, determinar los niveles de anticuerpos neutralizantes presentes en una muestra. La presente descripción abarca el reconocimiento de que los virus de HCMV que tienen una porción fluorescente, permiten la detección de la infección viral (por ejemplo, valorando la fluorescencia en las células después de poner en contacto la célula hospedera con el virus). En algunas modalidades, los niveles de infección por HCMV se determinan mediante la detección de la fluorescencia, en donde el virus se ha preincubado con una muestra de prueba (por ejemplo, una muestra de suero) de un sujeto. En algunas modalidades, se le ha administrado al sujeto una vacuna candidata para el HCMV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616204P | 2012-03-27 | 2012-03-27 | |
| PCT/IB2013/001021 WO2013144722A2 (en) | 2012-03-27 | 2013-03-27 | Methods for detection of anti-cytomegalovirus neutralizing antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014011504A MX2014011504A (es) | 2015-03-13 |
| MX354822B true MX354822B (es) | 2018-03-21 |
Family
ID=49261346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011504A MX354822B (es) | 2012-03-27 | 2013-03-27 | Metodos para la deteccion de anticuerpos neutralizantes anticitomegalovirus. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10006096B2 (es) |
| EP (2) | EP2831285B1 (es) |
| JP (1) | JP6265344B2 (es) |
| KR (2) | KR102314245B1 (es) |
| CN (1) | CN104321444A (es) |
| AU (2) | AU2013239383B2 (es) |
| BR (1) | BR112014023913B1 (es) |
| CA (1) | CA2867789C (es) |
| MX (1) | MX354822B (es) |
| RU (1) | RU2660712C2 (es) |
| WO (1) | WO2013144722A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2660712C2 (ru) * | 2012-03-27 | 2018-07-09 | Вэриэйшн Биотекнолоджиз, Инк. | Способы детекции антицитомегаловирусных нейтрализующих антител |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| JP6850483B2 (ja) * | 2018-03-06 | 2021-03-31 | 株式会社ＣｅＳＰＩＡ | Ｃｅｌｌ−ｂａｓｅｄ ａｓｓａｙ法に基づいたハイスループット抗体検出方法 |
| WO2019232453A1 (en) * | 2018-06-01 | 2019-12-05 | Gravid Therapies, Inc. | Methods, kits, and products for detection of cytomegalovirus infection |
| MX2021001769A (es) * | 2018-08-14 | 2021-04-19 | Merck Sharp & Dohme Llc | Un ensayo de neutralizacion de virus utilizando citometria de imagenes. |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CN111474339A (zh) * | 2020-04-17 | 2020-07-31 | 浙江康佰裕生物科技有限公司 | 一种利用荧光标记痘病毒颗粒的方法及其应用 |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| CN112362649B (zh) * | 2020-11-09 | 2024-07-12 | 长春金赛药业有限责任公司 | 一种rhGH中和抗体的检测方法 |
| CN112945919B (zh) * | 2021-01-29 | 2023-04-28 | 上海睿钰生物科技有限公司 | 一种病毒中和抗体的检测方法、系统及其应用 |
| WO2023141485A2 (en) * | 2022-01-19 | 2023-07-27 | Trustees Of Dartmouth College | Systems and methods for deterring viral transmission using neural networks |
| WO2023154857A2 (en) * | 2022-02-11 | 2023-08-17 | Trustees Of Dartmouth College | Systems and methods for identifying and treating primary and latent infections and/or determining time since infection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267965B1 (en) | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
| US5248768A (en) * | 1986-11-24 | 1993-09-28 | The Children's Hospital, Incorporated | Immunogenic glycoproteins of human cytomegalovirus |
| JPH06222062A (ja) | 1993-01-22 | 1994-08-12 | Teijin Ltd | ウイルス感染価および中和抗体価の測定法 |
| DE19910044A1 (de) | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
| US6569616B1 (en) * | 1999-07-29 | 2003-05-27 | Wisconsin Alumni Research Foundation | Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate |
| US6849409B2 (en) * | 2000-10-16 | 2005-02-01 | Axxima Pharmaceuticals Ag | Cellular kinases involved in Cytomegalovirus infection and their inhibition |
| CA2756797C (en) | 2002-12-23 | 2015-05-05 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| PT1651666E (pt) | 2003-07-11 | 2009-08-28 | Alphavax Inc | Vacinas de citomegalovírus à base de alfavírus |
| CN1686541A (zh) | 2005-04-11 | 2005-10-26 | 王明丽 | 人巨细胞病毒pp65蛋白质疫苗的制备方法 |
| KR20090064412A (ko) | 2006-09-01 | 2009-06-18 | 씨에스엘 리미티드 | 면역 반응을 유발 또는 유도하는 방법 |
| US9439960B2 (en) * | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
| ES2548014T3 (es) * | 2008-07-16 | 2015-10-13 | Institute For Research In Biomedicine | Anticuerpos neutralizantes del citomegalovirus humano y uso de los mismos |
| US20100267583A1 (en) * | 2009-04-15 | 2010-10-21 | Variation Biotechnologies Inc. | Method and kit for detection of hepatitis a virus neutralizing antibodies |
| US9145577B2 (en) | 2010-08-10 | 2015-09-29 | The Research Foundation Of State University Of New York | Lipoprotein lipase assay |
| KR102301463B1 (ko) * | 2011-11-11 | 2021-09-14 | 배리에이션 바이오테크놀로지스 아이엔씨. | 사이토메갈로바이러스의 치료를 위한 조성물 및 방법 |
| RU2660712C2 (ru) * | 2012-03-27 | 2018-07-09 | Вэриэйшн Биотекнолоджиз, Инк. | Способы детекции антицитомегаловирусных нейтрализующих антител |
-
2013
- 2013-03-27 RU RU2014142815A patent/RU2660712C2/ru active
- 2013-03-27 EP EP13769863.5A patent/EP2831285B1/en active Active
- 2013-03-27 KR KR1020207021568A patent/KR102314245B1/ko active IP Right Grant
- 2013-03-27 WO PCT/IB2013/001021 patent/WO2013144722A2/en active Application Filing
- 2013-03-27 KR KR1020147030138A patent/KR102146340B1/ko active IP Right Grant
- 2013-03-27 BR BR112014023913-4A patent/BR112014023913B1/pt active IP Right Grant
- 2013-03-27 US US14/387,870 patent/US10006096B2/en active Active
- 2013-03-27 EP EP19199107.4A patent/EP3613431B1/en active Active
- 2013-03-27 CA CA2867789A patent/CA2867789C/en active Active
- 2013-03-27 AU AU2013239383A patent/AU2013239383B2/en active Active
- 2013-03-27 CN CN201380026015.9A patent/CN104321444A/zh active Pending
- 2013-03-27 JP JP2015502478A patent/JP6265344B2/ja active Active
- 2013-03-27 MX MX2014011504A patent/MX354822B/es active IP Right Grant
-
2018
- 2018-05-29 US US15/991,044 patent/US10161010B2/en active Active
- 2018-11-27 AU AU2018271276A patent/AU2018271276B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3613431B1 (en) | 2023-01-11 |
| WO2013144722A3 (en) | 2013-11-28 |
| BR112014023913A2 (es) | 2017-06-20 |
| AU2018271276A1 (en) | 2018-12-20 |
| MX2014011504A (es) | 2015-03-13 |
| KR20200095575A (ko) | 2020-08-10 |
| RU2014142815A (ru) | 2016-05-20 |
| US20180274044A1 (en) | 2018-09-27 |
| AU2013239383B2 (en) | 2018-10-04 |
| CA2867789A1 (en) | 2013-10-03 |
| CA2867789C (en) | 2022-06-14 |
| WO2013144722A2 (en) | 2013-10-03 |
| BR112014023913B1 (pt) | 2022-08-09 |
| US10161010B2 (en) | 2018-12-25 |
| US20150044668A1 (en) | 2015-02-12 |
| EP2831285A4 (en) | 2015-10-28 |
| JP6265344B2 (ja) | 2018-01-24 |
| AU2013239383A1 (en) | 2014-10-16 |
| KR102146340B1 (ko) | 2020-08-24 |
| AU2018271276B2 (en) | 2021-06-03 |
| JP2015518140A (ja) | 2015-06-25 |
| US10006096B2 (en) | 2018-06-26 |
| KR20140146630A (ko) | 2014-12-26 |
| EP3613431A1 (en) | 2020-02-26 |
| KR102314245B1 (ko) | 2021-10-20 |
| CN104321444A (zh) | 2015-01-28 |
| EP2831285A2 (en) | 2015-02-04 |
| EP2831285B1 (en) | 2019-10-30 |
| RU2660712C2 (ru) | 2018-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014011504A (es) | Metodos para la deteccion de anticuerpos neutralizantes anticitomegalovirus. | |
| MX366275B (es) | Metodos para detectar y medir la agregacion. | |
| WO2013070776A8 (en) | Neutralizing gp41 antibodies and their use | |
| CY1119972T1 (el) | Προσδιορισμος για αντισωματα ιου jc | |
| WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
| MX2017005159A (es) | Composiciones y metodos para detectar un virus de rna. | |
| WO2009151628A3 (en) | Monitoring tcr-b to determine hiv therapy and disease progression | |
| WO2017079479A8 (en) | Neutralizing antibodies to hiv-1 gp41 and their use | |
| WO2012093340A3 (en) | Viral diagnostics | |
| EP4067507A3 (en) | Pna probes, kits and methods for detecting genotypes of human papillomavirus | |
| MX2019001767A (es) | Anticuerpos monoclonales que se unen al dominio de union a lipidos de la proteina de la capside del virus de la hepatitis c (vhc). | |
| BR112014029274A2 (pt) | anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira. | |
| WO2012037119A3 (en) | Inhibitors of viral entry into mammalian cells | |
| MX2015001961A (es) | Metodos y sistemas para ensayos. | |
| CL2012002900A1 (es) | Secuencias de acido nucleico procedente de un virus causante del sindrome de miocardiopatia (cms) en peces; vector; celula huesped; vacuna de adn; proteina recombinante codificada; vacuna recombinante; inmunoensayo para la deteccion de dicho virus; kit de diagnostico; y uso de las mismas. | |
| EA201891002A1 (ru) | Иммунологический анализ для определения расщепленного высокомолекулярного кининогена | |
| MX2016013584A (es) | Parvovirus porcino. | |
| WO2012103337A3 (en) | Assays and methods to sequence microbes directly from immune complexes | |
| WO2012162613A3 (en) | Detection of sequence variants in the human epidermal growth factor receptor (egfr) gene | |
| MY181007A (en) | Scale drop disease (sdd) causative virus and derivatives thereof | |
| WO2012169887A3 (en) | Use of new markers in a diagnostic assay for determining severity of rsv infection | |
| MX2014011045A (es) | Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib. | |
| WO2017009719A3 (ko) | 나노입자를 이용한 핵산 검출용 키트 및 핵산 검출 방법 | |
| WO2015061475A8 (en) | Compositions and methods for detection and discrimination of influenza viruses | |
| AU2014306512A8 (en) | Compositions and methods for detecting HEV nucleic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |